Overview

• A study published in eBioMedicine demonstrates that inhibiting the TYK2 protein can delay type 1 diabetes onset in preclinical models.
• Researchers found that TYK2 inhibition reduces pancreatic inflammation, preserves insulin-producing beta cells, and curbs immune system attacks.
• The drug, already FDA-approved for treating psoriasis, offers a faster pathway to human trials for type 1 diabetes patients.
• Genetic evidence supports the approach, showing that individuals with lower TYK2 activity are less likely to develop type 1 diabetes.
• Translational clinical trials are being planned to test the drug in individuals at risk for or recently diagnosed with type 1 diabetes.